Arm A for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, United StatesNon-Small Cell Lung CancerCarboplatin - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will study if ctDNA can help predict which NSCLC patients need immunotherapy and/or chemo to treat their cancer.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Duration of time from first treatment to time of death, up to 36 months

All analyses will be conducted using the 30-day safety window
Safety and Tolerability
Month 36
Duration of Response
Duration of time between the date of first treatment and the date of objectively documented progression per irRECIST or the date of initiation of palliative local therapy or the date of subsequent anti-cancer therapy, whichever occurs first, up to 36 mo
Objective Response Rate
Month 36
Overall Survival
Month 36
Progression Free Survival on Subsequent line of therapy (PFS2)
Month 36
Progression Free Survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Arm A
1 of 1

Active Control

108 Total Participants · 1 Treatment Group

Primary Treatment: Arm A · No Placebo Group · Phase 2

Arm AActiveComparator Group · 5 Interventions: Carboplatin, Nivolumab, Ipilimumab, Pemetrexed, Paclitaxel · Intervention Types: Drug, Drug, Drug, Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: duration of time from first treatment to time of death, up to 36 months

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor
119 Previous Clinical Trials
26,600 Total Patients Enrolled
39 Previous Clinical Trials
34,470 Total Patients Enrolled
Martin Gutierrez, MDPrincipal InvestigatorHackensack Meridian Health
1 Previous Clinical Trials
100 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 17 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 12 more weeks.
You are willing to have your blood tested multiple times to monitor your response to treatment.

Frequently Asked Questions

What is the current status of Arm A in terms of FDA validation?

"Our company has given Arm A a score of 2, as there is limited evidence that this drug can be safely administered, but no data to suggest its efficacy." - Anonymous Online Contributor

Unverified Answer

Are there remaining vacancies in this research investigation?

"As indicated on, the study which was initially published on February 15th 2023 has ceased recruitment of participants and is no longer accepting applications. However, there are 1329 other trials currently enrolling patients worldwide." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.